Intrinsiqs

Is Keros Therapeutics, Inc. overvalued?

Keros Therapeutics, Inc. (KROS) — key valuation metrics and fundamentals.

No verdict
Price
$10.89
Fair value
Current P/E
Normal P/E
Market cap
$347.6M
Dividend yield
Return on equity
Sector
Healthcare

See the full interactive analysis →

Fair value compares KROS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 30 Jun 2026.